EMAIL THIS PAGE TO A FRIEND

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Docetaxel enhances CD3+ CD56+ cytokine-induced killer cells-mediated killing through inducing tumor cells phenotype modulation.


PMID 25661332

Abstract

Pretreatment with chemotherapeutic agents could sensitize human lung adenocarcinoma cells to the lyses of cytokine-induced killer (CIK) cells, however, the mechanism still unclear. We hypothesized that chemotherapeutic agents could induced immunogenic modulation (IM) and calreticulin (CRT) expression and enhanced the cytokine-induced killer (CIK) cells-mediated killing. Here, using docetaxel, one of the most widely used cancer chemotherapeutic agents, as a model, we examined the molecular and immunogenic consequences of chemotherapeutic agent exposure in lung adenocarcinoma cell SPC-A1 cells. Our results showed that the human lung adenocarcinoma cells displayed an increased sensitization to lyses of CD3+ CD56+ CIK cells after treatment with nonlethal/sublethal doses of docetaxel in vitro. Docetaxel treatment of tumor cells did not induce ATP or high-mobility group box 1 (HMGB1) secretion, or cell death. However, calreticulin (CRT) exposure was observed. Enhanced killing by CIK cells was mediated largely by CRT membrane translocation, as determined by functional knockdown of CRT, or CRT blocking antibody. This study provides evidence that the pretreatment with chemotherapeutic agents can sensitize tumor cells to the lyses of CD3+ CD56+ CIK cells in vitro through inducing immunogenic modulation and upregulating in target cells.